Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2014
At a glance
- Drugs OPB 51602 (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 10 Jun 2017 Biomarkers information updated
- 14 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record
- 11 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.